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Abstract: The analytical, comparative cross-sectional study was conducted to assess the thyroid profiles and modified lipid profiles 
levels among Sudanese patients with coronary heart disease performed on forty-one patients with coronary heart disease as test 
group collected from Sudan Heart Center, Al rebat teaching hospital and Al mawada hospital in Khartoum state, during the period 
between November 2017 and May 2018. Furthermore, the test group compared with forty-one apparently healthy volunteers as 
control group was selected with the same inclusion criteria.  
Spectrophotometeric methods were used for measurement of lipid profile. Thyroid hormones (T3 &T4) and thyroid stimulating 
hormone were measured by using Sandwich Enzyme-Linked Immunosorbent Assay (ELISA). Moreover, statistical package for 
social science (SPSS version 23) computer software was used for data analysis. 
The study clearly demonstrated that there was statistically significant decrease in T3, and significant increase in T4 levels in test 
group compared to control with (P. value 0.047) for T3, and (P. value 0.002) for T4.Nonetheless, the result of this study indicated 
a significant elevation in mean of total cholesterol, low density lipoprotein-cholesterol levels and significant decrease in high 
density lipoprotein –cholesterol in test group compared to control (P.value 0.000). 
In conclusion Coronary heart diseases patients have significantly low Triiodothyronine, elevated Thyroxin, and normal Thyroid 
Stimulating Hormone levels, with significantly higher Total Cholesterol, Low Density Lipoprotein-Cholesterol concentrations, and 
lower HighDensity Lipoprotein-Cholesterol concentrations. 
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1. INTRODUCTION 
Coronary heart disease is believed to start with injury or 
damage to the inner layer of a coronary artery, this damage 
causes fatty plaque deposits on build up at the site of the 
injury, these deposits consist of cholesterol another cellular 
waste products, the accumulation is called atherosclerosis(1). 
Furthermore, this imbalance between the myocardial oxygen 
demand and the blood supply leading to reduction in the 
blood flow, this reduction may not produce any symptoms 
but as fatty deposits or plaques. Depending on the rate 
severity of coronary artery narrowing and myocardial 
response one of the four syndromes may develop includes 
angina (heart pain or discomfort) heart attack, heart failure 
and cardiac arrhythmias.Once the plaques have formed or 
rupture platelets will clump in the area, attempting to repair 
the blood vessels, this clump damaged the wall of the 
coronary artery that reducing or blocking blood flow, and 
leading to heart attack(2). 
 Lipid profiles is the collective term given to the estimation 
of total cholesterol (TC), high-density lipoprotein cholesterol 
(HDL-C), low-density lipoprotein cholesterol (LDL-C), and 
triglycerides (TG). An extended lipid profile may include 
very low-density lipoprotein cholesterol (VLDL-C)(3). 
However, this is used to identify dyslipidemia (various 
disturbances of cholesterol and triglyceride levels); many 
forms of which are recognized as risk factors for 
cardiovascular disease and sometimes pancreatitis(3). 
A total cholesterol reading can be used to assess an 
individual's risk for heart disease; it should not be relied 
upon as the only indicator. The individual components that 
make up total cholesterol reading LDL, HDL, and VLDL are 
also important in measuring risk(3).  
Dyslipidemia are characterized by disorders in the levels of 
circulating lipids total cholesterol (TC) or triglycerides (TG), 
or low levels of high densitylipoprotein cholesterol (HDL-
C), with or without repercussion of the vascular territory, 
associated to many clinical manifestations (3). 
They can be influenced by genetic and/or acquired disorders. 
Among the environmental variables involved in determining 
the lipid profile, smoking, sedentary lifestyle and diet are 
included. Excessive caloric ingestion, with high rate of fat 
and cholesterol, is associated to increased serum levels of 
total cholesterol (TC) and fraction cholesterol of low-density 
lipoprotein (LDL-C). Among adults, the increased 
concentration of TC and diminished fraction of high density 
lipoprotein (HDL-C) cholesterol, hypertension, smoking, 
diabetes and obesity are associated to advanced 
atherosclerosis lesions and a greater risk of clinical 
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manifestations of atherosclerotic disease. There are also 
other factors involved, but non-controllable; those are age, 
sex, race and heredity (3). 
Hyperlipidemiarefers to elevated levels of lipids and 
cholesterol in the blood, and is also identified as 
dyslipidemia, to describe the manifestations of different 
disorders of lipoprotein metabolism. Although elevated low 
density lipoprotein cholesterol (LDL) is thought to be the 
best indicator of atherosclerosis risk (4). 
Thyroid hormones are essential for normal development, 
growth and metabolic balance; it also plays an important role 
in carbohydrate metabolism andprotein synthesis, and they 
increase calorigenesis andoxygen consumption in most 
tissues(5). 
Thyroid hormones may lead to increase in heart rate and 
cardiac output; due to it is ability to increase the sensitivity 
of the cardiovascular and nervous system to catecholamine’s 
(5). 
Thyroid hormones play a major role in regulating lipid 
metabolism, thus thyroid dysfunctions can result in lipid 
abnormalities and increase the risk to develop hypertension, 
endothelial dysfunction and cardiovascular disease(6). 
Furthermore, the relationship between thyroid hormones and 
lipid metabolism is clearly displayed in patients suffering 
from thyroid dysfunctions. Overt hypothyroid patients show 
elevated cholesterol and triglyceride (TG) levels while overt 
hyperthyroid patients show reduced lipid levels. These 
observations have been shown to extend into the subclinical 
hypo/hyperthyroid range, suggesting that apart from thyroid 
hormones, thyroid-stimulating hormone (TSH) exerts 
independent effects on lipid metabolism. Moreover, thyroid 
hormones have been shown to induce the expressions of 3-
hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA) 
reductase (responsible for cholesterol synthesis), low density 
lipoprotein receptor (LDLR) via sterol regulatory element-
binding protein-2 (SREBP-2) (responsible the uptake of 
cholesterol), lipoprotein lipase (responsible for catabolizing 
TG-rich lipoprotein), cholesteryl ester transfer protein 
(responsible for high density lipoprotein (HDL) metabolism) 
and apolipoprotein AV (which reduces the production of 
hepatic very low density lipoprotein (VLDL)-TG). Thyroid-
stimulating hormone has also been shown to induce 
adipogenesis, lipolysis and increase the activity of HMG-
CoA(7). Nonetheless, the lipid profile changes are reversible 
with the thyroid hormonesreplacement (7). 
The most common cause of CHD is narrowing of the lamina 
of the coronary arteries by atherosclerosis. Initially, an area 
of atheromatous plaque forms in the coronary artery.  The 
mechanism   for   plaque   formation   is unclear, although 
the predominant view is that lipid accumulates under the 
lining of the coronary artery. Because the lipid infiltrate is a 
foreign matter, white blood cells called macrophages engulf 
it, and create foam cells. Smooth muscle cells then invade 
the area, which enlarges the plaque and obstructs more than 
50% of the lumen of the coronary artery that the flow of 
blood to the heart muscle, the myocardium, is reduced; 
(8)
 
while resting, or undertaking a minimal activity, the blood 
supply to the heart is adequate. However, when the heart 
requires a greater supply of oxygen, as occurs during 
exercise or emotional episodes, the blood supply cannot 
increase sufficiently and the person will experience chest 
discomfort. This is referred to as angina pectoris. Once 
plaque has formed, the wall of the coronary artery is 
damaged and irregular in shape and platelets cluster around 
the obstruction. This reduces the size of the lumen still 
further and consequently the blood supply is also reduced(8)  
Long term hypothyroidism is associated with severe 
cardiovascular manifestation including increased systemic 
vascular resistance, reduced contractibility and cardiac 
oxygen consumption and raised diastolic hypertension (9). 
The association of thyroid dysfunctions with 
hypercholesterolemia and hypertension makes the thyroid 
dysfunctions patients more predispose to accelerated 
atherosclerosis and coronary heart disease than others(9). 
Prevalence of coronary heart disease (CHD) is increased in 
Sudan. Dyslipidemia is most common risk factor for the 
development of CHD. Nonetheless, Thyroid hormones has 
role in lipid metabolism, hence that TSH regulates the key 
enzyme in cholesterol synthesis and has a role in maintaining 
lipid homeostasis.  
The study was aim to assess the thyroid hormones, modified 
lipid profile levels in Sudanese patients with CHD in 
comparison with healthy control group.  
The objectives of this research were;  
-To measure serum TSH, T3, T4, Total cholesterol, HDL-C, 
LDL-C levels in CHD patients and control group. 
-To compare serum TSH, T3, T4, Total cholesterol, HDL-C, 
LDL-C levels among Sudanese patients with CHD with 
healthy control group. 
2. MATERIALS AND METHODS 
Thisis an analytical, comparative cross-sectional, hospital 
based study. It was conductedin Sudan Heart Center, Al 
rebat teaching hospital and Al mawada hospital in Khartoum 
state, during the period from 2017 to 2018. 
 A total of Forty-one patients with coronary heart disease 
(Test group) were included in the study, compared with 
Forty-one apparently healthy controls matched for age and 
sex.Patients with History of diabetes mellitus, autoimmune 
disease and familial dyslipidemia were excluded from the 
study. 
The permission of this study was obtained from Nile college 
academic affair. The objectives of the study were 
explainedto all individuals participated in the study. Oral 
consent was obtained from each participant in the study. 
After taken an oral consent and used alcohol swab 
(70%ethanol) as antiseptic for skin, a sample of venous 
blood (3 ml)was collected from each participant in this 
study, usingdisposable plastic syringe. The blood was 
collected from the armdirectly in lithium heparin container. 
The containers were then centrifuged at 3000 rpm for 
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3minutes and obtained plasma. The plasma prepared was 
stored at-250 c until used. 
Spectrophotometeric methods were used for measurement of 
total cholesterol, HDL-C, and LDL-C levels. Thyroid 
hormones (T3 &T4) and thyroid stimulating hormone were 
measured by using Sandwich Enzyme-Linked 
Immunosorbent Assay (ELISA). The precision and accuracy 
of all methods used in this study were checked each time; a 
batch was analyzed by including commercially prepared 
control sera. Statistical Package for Social Science (SPSS 
version 23) computer software was used for data analysis 
(Significance levels were set at P≤0.05). Independent t-test 
was used to compare between test group and healthy control 
group. 
3. RESULTS: 
In the present study, total of 82 subjects were divided into 
two groups, 41 healthy controls   and 41cases (CHD 
patients), were included. 
It was evident that T3 and T4 levels were decreased in cases 
as compared to controls with p value 0.047for T3, and 0.002 
for T4(Table1). 
It was evident that TC, LDL-C, and HDL-C levels were 
increased in cases as compared to controls with P value 
0.000 (Table1). 
Table (1): Comparison of T3, T4, TSH and Lipid Profile between CHD patients and healthy controls: 
Parameters Case(N=41) 
Mean ± SD 
Control(N=41) 
Mean ± SD 
P- value 
TSH ( (μlU/ml)) 1.48 ± 0.68 1.47 ± 0.63 0.950 
T3 ( ng/ml) 
 
2.12 ± 0.94 2.45 ± 0.35 0.047 
T4 (μg/dl) 
 
11.26 ± 2.27 9.75 ± 2.08 0.002 
Cholesterol (mg/dl) 250 ± 49 155 ± 25 0.000 
LDL-C (mg/dl) 177 ± 28 91 ± 24.4 0.000 
HDL-C (mg/dl) 31 ± 7.5 70 ± 17.6 0.000 
 
-The table shows the mean ±SD. deviation and probability 
value (p-value). 
- Independent t-test was used for comparison. 
- P value ≤ 0.05 is considered significant. 
4. DISCUSSION: 
Prevalence of coronary heart disease (CHD) is increased in 
Sudan, high mortality rate.Arteriosclerosis is not clinically 
evident until middle age or later, when the arterial lesions 
precipitate the organ injury (10). The association of thyroid 
dysfunctions with hypercholesterolemia and hypertension 
makes the thyroid dysfunctions patients more predispose to 
accelerated atherosclerosis and coronary heart disease than 
others. 
Our study was found that most of the CHD patients have 
TSH level within normal range no statistically significant 
difference between case and control values (p value 0.950), 
another study reported that CHD patient had high levels of 
TSH, hypothyroidism is associated with dyslipidemia having 
raise in all lipid parameters, which may increase the risk of 
cardiovascular diseases. This finding was reported by 
BandiA  (11) .This difference from the current study may be 
due to small sample size used limited period and therefore 
the results inferred may not be considered as the reflection of 
larger population. 
In our study, there was a weakly significant difference 
between case and control values ofT3 (p value 0.047) similar 
findings were observed by Singh PA(12).Who found that the 
(T3) levels significantly decreased when compared to 
control, and highly significant difference between case and 
control values of T4(p value 0.002). 
Furthermore, the current study showedthat CHD patient has 
high levels of TC, LDL-C, and HDL-C, compared with 
controls (p value 0.000). Similar findings were observed by 
Al-Hakeim HK(13)and Archana Prakash(14). 
5. CONCLUSION: 
 In conclusion coronary heart diseases patients have 
significantly lower Triiodothyronine, increased Thyroxin, 
and normal Thyroid Stimulating Hormone levels, with 
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significantly higher Total Cholesterol, Low Density 
Lipoprotein-Cholesterol concentrations, and lower High 
Density Lipoprotein-Cholesterol concentrations.  
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